Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: WYD who wrote (4483)	10/15/2002 2:17:57 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

Scott, if you look for posts by Cathi over on RB, you'll find a post where heart complications with Herceptin are thought to be at least part of the reason. Others on RB think DNA is comparing results with what SGEN is providing to them, and I for one think they may also be looking at similar TAP drugs they have under development, and determining which is best. I think the reality is, Herceptin-DM1 may not come into the clinic, but if it doesn't, it will be because they have something better. Hopefully, it will also come out of the partnership with IMGN. Gary